Effect of Cabergoline on biochemical and anthropometric parameters of patients with prediabetes.

Phase 2

• Conditions: Impaired Glucose Tolerance/Impaired Fasting Glucos.; Impaired glucose tolerance (oral); R73.02

• Registration Number: IRCT20170608034390N6
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 98

Inclusion Criteria

Patients with Impaired Fasting Glucose and/or Impaired Glucose Tolerance
Adults (18-65 years)

Exclusion Criteria

Severe hepatic failure (Child-Pugh scores of 10 or higher)
History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders
Hypersensitivity to ergot derivatives
Uncontrolled hypertension
Diabetes
Pregnant Women
Lactating Women
Major psychiatric disorders
Patients who are receiving medications which affect prolactin secretion
Bulimia or/and anorexia nervosa

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting Plasma Glucose. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Autoanalyzer.;2h plasma glucose. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: ???????????.;Hb A1c. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: HPLC.;2h Insulin. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: ??????.;Wheight. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Scale.;Height. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Standard Meter.;Wrist circumference. Timepoint: Before participation, 4 weeks later and 8 weeks later. Method of measurement: Standard Meter.